FDA approves Biogen’s aducanumab
Aduhelm (aducanumab) is the first new dementia drug treatment to come to market since 2003.
News & events
News, conferences, events, blogs and updates from across the field of dementia and the work of Alzheimer's Disease International.
Featured news and events
Life in a dementia care centre during India’s second COVID-19 wave: Part one
In this four part series, Senju Joseph, a carer at the Dementia Respite care centre in Thrissur, India, documents his experience of navigating the catastrophic second COVID-19 wave.
African regional member meeting
ADI members in the African region took part in their first regional meeting of 2021 and since the COVID-19 pandemic began in early 2020.
World Alzheimer Report 2020 wins European Healthcare Design award
The World Alzheimer Report 2020 has been awarded the European Healthcare Design (EHD) 2021 Award for Outstanding Contribution to Global Knowledge.
ADI submits World Health Assembly statement on COVID-19, dementia and future preparedness
As the 74th World Health Assembly begins, ADI is sharing a statement submitted to the World Health Organization (WHO) and Member States.
European and Caribbean regional member meetings
ADI members in the European and Caribbean regions took part in the first regional meetings of 2021 and since the COVID-19 pandemic began in early 2020.
ADI Council votes on new members, Board appointees
ADI is pleased to welcome 6 new member associations, as well as new members to the ADI board.
Medical and Scientific Advisory Panel (MSAP) meeting
During the 60-minute meeting, the advisory panel discussed ADI's activities over the last year, as well as proposals for future avenues of research, including a working group to explore the impact of COVID-19 as a potential risk factor for accelerating dementia.
ADI Council Meeting of 2021
The ADI Council met on 30 March 2021 to discuss ADI's activities over 2020, new membership applications and more.
Eli Lilly presents results for Phase 2 TRAILBLAZER-ALZ trial for donanemab
Phase II trial results found that donanemab slowed cognitive and functional decline in patients with early symptomatic Alzheimer's disease.